 |
| Ypsomed enters new partnerships in diabetes therapy |
| | Burgdorf, 22.10.2019, 7.00 a.m. – By entering into new partnerships and cooperations, Ypsomed has expanded its diabetes therapy offerings. With the goal of freedom of choice for the users of the mylife™ YpsoPump®, the first study on the insulin pump with open interfaces as well as the connection to the therapy management solution diasend® by Glooko starts. In addition, Ypsomed launches the new blood glucose monitoring system mylife™ Aveo™ in spring 2020. | Expansion in the digital therapy management
Ypsomed’s insulin pump mylife™ YpsoPump® is now readable via the therapy management software diasend® by Glooko. Therapy data from the mylife™ App can be sent to diasend® via a secure Cloud-to-Cloud connection. The data transfer to software solutions of third-party suppliers offers the users of the mylife™ YpsoPump® even more freedom of choice regarding their therapy and makes the communication between user and physician easier. „Thanks to our cooperation with third-party suppliers of therapy management solutions such as Glooko, we can further expand our approach of modularity and free choice in the insulin therapy as well as continue our efforts to establish an open insulin pump system. Additionally, we create a real therapeutic added value for our customers”, comments Dr Eberhard Bauer, Senior Vice President Ypsomed Diabetes Care.
First clinical studies with an interoperable mylife™ YpsoPump®
Last year, Ypsomed announced its participation in the “Open-Protocol Automated Insulin Delivery (AID) Systems Initiative” of JDRF. The aim of the collaboration is the development and approval of the next generation mylife™ YpsoPump® insulin pump, which supports the integration of smartphone apps and third-party devices for more automated insulin delivery in order to enable people with type 1 diabetes to choose their own therapy option. To further develop the mylife™ YpsoPump® and establish an open pump concept, Ypsomed provides an interoperable and open insulin pump for an investigator initiated study at the renowned Baker Institute in Melbourne, Australia. The study will prove the benefit of an individualised therapy with an open insulin pump and will continue to push the development of open systems.
„There is a clear need of clinical studies in this field. These will provide important evidence of the security as well as effectiveness of open pump systems and will speed up the approval. The Baker Institute in Melbourne is now starting the world’s first trials with an open mylife™ YpsoPump®. Our clinical trial group has developed a study protocol which will serve as a basis for the regulatory approval upon successful completion”, comments Neale Cohen, Director of Clinical Diabetes at the Baker Heart and Diabetes Institute in Melbourne. |  | Distribution partnership with i-SENS for the new blood glucose monitoring system
Ypsomed launches a new blood glucose monitoring system. For this purpose, Ypsomed has entered a distribution partnership with i-SENS, Inc., a global manufacturer of biosensors based in South Korea. The blood glucose monitoring system developed and manufactured by i-SENS will be launched by Ypsomed under the brand name mylife™ Aveo™ in selected markets in spring 2020. „As part of our growth strategy, we are enlarging our product portfolio and expanding territorially. For this, we need partners such as i-SENS who manufacture reliable products and offer an interesting and future-oriented portfolio”, explains Dr Eberhard Bauer, Senior Vice President Ypsomed Diabetes Care.
Download press release as PDF file
|
|
| Thomas Kutt
Leiter Investor Relations
Ypsomed Holding AG
T +41 34 424 35 55
Email senden | |
|
|
|
| | Ypsomed ist die führende Entwicklerin und Herstellerin von Injektions- und Infusionssystemen für die Selbstmedikation und ausgewiesene Diabetesspezialistin mit 30 Jahren Erfahrung. Als Innovations- und Technologieführerin ist sie bevorzugte Partnerin von Pharma- und Biotechunternehmen für Pens, Autoinjektoren und Pumpensystemen zur Verabreichung von flüssigen Medikamenten. Ypsomed präsentiert und vertreibt ihre Produktportfolios unter den Dachmarken mylife™ Diabetescare direkt an Patienten oder über Apotheken und Kliniken sowie unter YDS Ypsomed Delivery Systems im Business-to-Business-Geschäft an Pharmafirmen. Sie hat ihren Hauptsitz in Burgdorf, Schweiz, und verfügt über ein globales Netzwerk aus Produktionsstandorten, Tochtergesellschaften und Vertriebspartnern und beschäftigt weltweit rund 1‘700 Mitarbeitende. Weitere Informationen finden Sie auf www.ypsomed.com. | |
|
|
|
|
